GGrantIndex
Sort

64,565 grants matching drug discovery

Discovery of Antibiotics from Soil Microbiomes Using Metagenomics

$678,000
Sean F Brady · Rockefeller University · R35 · FY2020 · GM

Mechanisms and targeting of aberrant Gas activation in myeloid neoplasms

$677,959
Eirini Papapetrou · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA

Discovery of novel therapeutic targets for NASH through deep phenotyping of human knockouts and mechanistic studies

$677,927
Danish Saleheen · Columbia University Health Sciences · R01 · FY2022 · DK

Structural Biology & Biophysics Core (SBB)

$677,889
Andrew D Mesecar · Indiana University Indianapolis · U54 · FY2025 · AG

UC San Diego Clinical and Translational Research Institute

$677,865
Colin A Depp · University Of California, San Diego · TL1 · FY2018 · TR

Single-cell Analysis of Normal and Perturbed Dynamic Biological Systems

$677,833
Benedict Anchang · National Institute Of Environmental Health Sciences · ZIA · FY2022 · ES

Engineered Stem Cells for Cardiac Repair

$677,801
Michael Regnier · University Of Washington · R01 · FY2020 · HL

Role of Host Protein Kinase C in Cryptosporidiosis

$677,703
Chelsea S. Marie · University Of Virginia · R01 · FY2023 · AI

Salmonella-specific therapeutics

$677,686
Brian M Ahmer · Ohio State University · R01 · FY2020 · AI

Nuclear Factor-kappaB in Ovarian Cancer

$677,683
Christina Annunziata · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

Designing drugs that suppress chronic brain inflammation

$677,640
Inflame Therapeutics, Inc. · R43 · FY2005 · NS

Development Of Drugs Acting At Adenosine Receptors

$677,639
Kenneth Alan Jacobson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2017 · DK

Optimization of EP2 Antagonists for Post-Seizure Cognitive Deficits

$677,532
Thota Ganesh · Emory University · UG3 · FY2022 · NS

Development of vector-specific, resistance-breaking insecticides to reduce malari

$677,523
Paul R Carlier · Virginia Polytechnic Inst And St Univ · R01 · FY2011 · AI

Pan-filovirus antivirals targeting the VP35 protein

$677,475
Christopher F Basler · Icahn School Of Medicine At Mount Sinai · R56 · FY2010 · AI

Development of a Phenotype-based Predictive Analytic for Acute Myeloid Leukemia

$677,289
Michael R Savona · Vanderbilt University Medical Center · R01 · FY2025 · CA

Behavioral Phenotyping Core

$677,286
Leona Gagnon · Jackson Laboratory · P50 · FY2023 · DA

Positive Allosteric Modulators as PET Imaging Ligans for mGluR4

$677,276
Anna-Liisa Brownell · Massachusetts General Hospital · R01 · FY2019 · NS

Evolution of drug resistance in Candida glabrata

$677,183
Gavin J Sherlock · Stanford University · R01 · FY2021 · AI

Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP

$677,137
Peter Alexander Ljubenkov · University Of California, San Francisco · R01 · FY2021 · AG

Behavioral Pharmacology of Cannabinoid and Terpenoid Effects and Interactions

$677,123
Ryan G Vandrey · Johns Hopkins University · R01 · FY2021 · DA

Modeling hyperactivity in neurological disease using patient-derived pluripotent stem cells

$677,095
Fred H Gage · University Of Pennsylvania · U19 · FY2018 · MH

Schizophrenia interactome mapping and global discovery of brain splice variants

$677,081
Lilia M Iakoucheva · University Of California, San Diego · R01 · FY2012 · MH

The role of cardiolipin in the biogenesis of the Gram-negative bacterial cell envelope

$677,076
Michael Stephen Trent · University Of Georgia · R01 · FY2023 · AI

Targeting neuroinflammation in AD with novel CX3CR1 agonists

$677,072
Layton Harris Smith · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2021 · AG